Back to Search
Start Over
Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion.
- Source :
-
Advances in rheumatology (London, England) [Adv Rheumatol] 2018 Aug 03; Vol. 58 (1), pp. 22. Date of Electronic Publication: 2018 Aug 03. - Publication Year :
- 2018
-
Abstract
- Introduction: Infliximab infusion generally occurs in 2-4 h. Recent studies have suggested the possibility of accelerated infusion (1 h) of this drug.<br />Objective: To evaluate the safety of accelerated infliximab infusion in patients with rheumatic diseases. In addition, patient satisfaction was also assessed.<br />Methods: A prospective, single-center, non-randomized study with 34 patients with rheumatic diseases was conducted from July to November 2016. Patients with the following were excluded: history of allergic reaction to biologics, asthma or severe atopy. All patients previously received a 2- to 3-h infliximab infusion. The infusion rate was accelerated to 1 h, and premedication was excluded. The infusion was monitored in all patients.<br />Results: A total of 34 patients were included in the study [rheumatoid arthritis (n = 16), ankylosing spondylitis (n = 15), psoriatic arthritis (n = 2) and enteropathic arthropathy (n = 1)], with an average age of 48.7 ± 18.6 years; 55.5% of the patients were female, and 29.4% were white. The duration of disease was 9.5 ± 9.2 years, and the duration of infliximab use was 38.9 ± 27.6 months, with a mean dose per infusion of 414.2 ± 158.1 (range, 200-800) mg. The mean infliximab infusion time prior to the study was 2.2 ± 0.4 h. A total of 6 (17.6%) patients received premedication. The premedication was suspended. There were no adverse effects during or after infusion. Ninety-seven percent of the patients and 100% of the health workers were satisfied with the accelerated infusion.<br />Conclusion: Our data support the safe use of accelerated infliximab infusion in rheumatic patients, with high satisfaction among patients and health workers.
- Subjects :
- Adult
Aged
Antirheumatic Agents adverse effects
Arthritis, Psoriatic drug therapy
Arthritis, Psoriatic psychology
Arthritis, Rheumatoid drug therapy
Arthritis, Rheumatoid psychology
Crohn Disease drug therapy
Crohn Disease psychology
Drug Administration Schedule
Female
Humans
Infliximab adverse effects
Infusions, Intravenous adverse effects
Infusions, Intravenous methods
Male
Middle Aged
Prospective Studies
Spondylitis, Ankylosing drug therapy
Spondylitis, Ankylosing psychology
Time Factors
Young Adult
Antirheumatic Agents administration & dosage
Infliximab administration & dosage
Patient Satisfaction
Rheumatic Diseases drug therapy
Rheumatic Diseases psychology
Subjects
Details
- Language :
- English
- ISSN :
- 2523-3106
- Volume :
- 58
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Advances in rheumatology (London, England)
- Publication Type :
- Academic Journal
- Accession number :
- 30657070
- Full Text :
- https://doi.org/10.1186/s42358-018-0016-x